National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 443797

History of Changes from the VAERS Wayback Machine

First Appeared on 3/12/2012

443797
VAERS Form:
Age:
Gender:Unknown
Location:Foreign
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2011-11-28
Entered:2011-11-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UN / UN

Administered by: Unknown      Purchased by: Unknown
Symptoms: Arthralgia, Headache, Lymphadenopathy, Muscular weakness, Paraesthesia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1111USA02625

Write-up:Information has been received from health authority (local reference No. NZL/11/0102) concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL (lot number, dose and site of administration not reported). On unspecified date, the patient experienced paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness. At the time of the report, the patient''s paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness persisted. Paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were considered to be disabling by the agency. The reporter felt that paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were related to therapy with GARDASIL. The original reporting source was not provided. No further information is available.


Changed on 6/14/2014

443797 Before After
VAERS Form:
Age:
Gender:Unknown
Location:Foreign
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2011-11-28
Entered:2011-11-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UN / UN

Administered by: Unknown      Purchased by: Unknown
Symptoms: Arthralgia, Headache, Lymphadenopathy, Muscular weakness, Paraesthesia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1111USA02625

Write-up:Information has been received from health authority (local reference No. NZL/11/0102) concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL (lot number, dose and site of administration not reported). On unspecified date, the patient experienced paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness. At the time of the report, the patient''s paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness persisted. Paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were considered to be disabling by the agency. The reporter felt that paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were related to therapy with GARDASIL. The original reporting source was not provided. No further information is available.


Changed on 3/14/2015

443797 Before After
VAERS Form:
Age:
Gender:Unknown
Location:Foreign
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2011-11-28
Entered:2011-11-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UN / UN

Administered by: Unknown      Purchased by: Unknown
Symptoms: Arthralgia, Headache, Lymphadenopathy, Muscular weakness, Paraesthesia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1111USA02625

Write-up:Information has been received from health authority (local reference No. NZL/11/0102) concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL (lot number, dose and site of administration not reported). On unspecified date, the patient experienced paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness. At the time of the report, the patient''s paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness persisted. Paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were considered to be disabling by the agency. The reporter felt that paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were related to therapy with GARDASIL. The original reporting source was not provided. No further information is available.


Changed on 9/14/2017

443797 Before After
VAERS Form:(blank) 1
Age:
Gender:Unknown
Location:Foreign
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2011-11-28
Entered:2011-11-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UNK UN / UN

Administered by: Unknown      Purchased by: Unknown
Symptoms: Arthralgia, Headache, Lymphadenopathy, Muscular weakness, Paraesthesia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1111USA02625

Write-up:Information has been received from health authority (local reference No. NZL/11/0102) concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL (lot number, dose and site of administration not reported). On unspecified date, the patient experienced paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness. At the time of the report, the patient''s paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness persisted. Paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were considered to be disabling by the agency. The reporter felt that paraesthesia, lymphadenopathy, arthralgia, headache and muscle weakness were related to therapy with GARDASIL. The original reporting source was not provided. No further information is available.


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=443797&WAYBACKHISTORY=ON


Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166